Financial Data and Key Metrics Changes - Total revenue for Q2 2026 was $15 million, an increase of 11% year-over-year from $13.5 million, driven by improved conversion of booked work due to a lower level of cancellations [8][9] - Income from operations for the quarter was $185,000, and adjusted EBITDA was approximately $800,000, with the company on track to achieve full-year positive adjusted EBITDA [8][9] - Gross margin improved to 52% compared to 45% last year, supported by flat cost of sales despite increased revenue [9] Business Line Data and Key Metrics Changes - The company reported continued success in radiolabeling and radiopharmaceutical support workflows, which are becoming increasingly significant in oncology drug development [4][5] - Investments in the data platform are ongoing, enhancing its functionality and expanding utility for pharma partners, which is viewed as a critical long-term value driver [5][6] Market Data and Key Metrics Changes - The broader environment shows gradual improvement across pharma and biotech budgets, with customer engagement and opportunity pipeline generation improving relative to the previous year and a half [3] - A recent survey indicated that over a third of biotech executives plan to increase outsourcing next year, suggesting a positive trend for the company's services [15] Company Strategy and Development Direction - The company aims to deliver year-on-year revenue growth, invest in growth levers like data platforms, and maintain fiscal discipline to avoid shareholder dilution [2][3] - Focus remains on execution, maximizing conversion of existing bookings, improving operational efficiency, and advancing capabilities to distinguish the company in the market [3][7] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for booking momentum in the next calendar year as R&D budgets reset for 2026 [3] - The company is encouraged by improved operational discipline, a strengthening commercial position, and strategic investments in areas with competitive advantages [7][11] Other Important Information - The company ended the quarter with $8.5 million in cash and no debt, maintaining a solid financial position [10] - Corelia, a wholly-owned subsidiary focused on target discovery, is making progress in discussions with potential venture capital funding partners [6] Q&A Session Summary Question: Has there been an uptick in inbound call volume regarding RFPs, and how quickly can the company return to double-digit revenue growth? - Management noted optimism regarding opportunity generation and improvements in the market, with investments in the commercial team positioning the company well for recovery [15] Question: Are sales and marketing investments targeting the data opportunity exclusively? - Management highlighted a recent hire to lead the data business, emphasizing the strategic mindset and domain expertise brought to the team [16] Question: What are the expectations for gross margins moving forward? - Management indicated that gross margins for the service business are expected to remain in the 50%-52% range, with potential fluctuations due to various expenses [19][20] Question: Can the company provide updates on Corelia's drug candidates and potential valuations? - Management refrained from sharing specific details but expressed excitement about the data and traction with VC partners [22]

Financial Data and Key Metrics Changes - Total revenue for Q2 2026 was $15 million, an increase of 11% year-over-year from $13.5 million in Q2 2025, driven by improved conversion of booked work due to a lower level of cancellations [9][10] - Gross margin improved to 52% compared to 45% in the same quarter last year, supported by operational efficiencies [10] - Adjusted EBITDA for the quarter was approximately $800,000, with income from operations at $185,000 [9][10] Business Line Data and Key Metrics Changes - The company reported continued success in radiolabeling and radiopharmaceutical support workflows, which are expected to become increasingly significant in their service offerings [4][5] - Investments in the data platform are ongoing, enhancing its functionality and expanding utility for pharma partners, which is viewed as a critical long-term value driver [5][6] Market Data and Key Metrics Changes - The broader pharma and biotech budgets are gradually improving, with customer engagement and opportunity pipeline generation showing signs of recovery [3] - A recent survey indicated that over a third of biotech executives plan to increase outsourcing next year, reflecting a positive trend in the market [15] Company Strategy and Development Direction - The company aims to deliver year-on-year revenue growth, invest in growth levers like data platforms, and maintain fiscal discipline to achieve positive Adjusted EBITDA without shareholder dilution [2][3] - The focus remains on execution, maximizing conversion of existing bookings, and improving operational efficiency [3][8] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding booking momentum as R&D budgets reset for calendar 2026, indicating a potential for improved performance in the next year [3] - The company is encouraged by its operational discipline and strategic investments in areas where it holds competitive advantages, such as its tumor bank and data platform [7][8] Other Important Information - Corelia, a wholly-owned subsidiary focused on target discovery, is making progress in discussions with potential venture capital partners, with plans to redirect investment dollars toward accelerating growth in the data business once external funding is secured [6] Q&A Session Summary Question: Has there been an uptick in inbound call volume regarding RFPs? - Management noted an improvement in opportunity generation and optimism about the market recovery, with a survey indicating increased outsourcing plans among biotech executives [15] Question: Are sales and marketing investments targeting the data opportunity exclusively? - Management highlighted a recent hire, Dr. Tamir Farid, to lead the data business, emphasizing the strategic and domain expertise he brings to enhance growth opportunities [16] Question: What are the expectations for gross margins moving forward? - Management expects gross margins for the service business to remain in the 50%-52% range, with potential fluctuations due to various expenses, including outsourced lab service costs [19][20] Question: Can you comment on the progress of Corelia's drug candidates? - Management refrained from sharing specific details but expressed excitement about the data and traction with venture capital partners, indicating that more information will be shared in the future [23]

Financial Data and Key Metrics Changes - Revenue for Q3 2026 was $195 million, representing a 29% year-over-year increase [16] - Non-GAAP operating margin reached 13%, an improvement of nearly 9 percentage points year-over-year [6][18] - Non-GAAP gross margin expanded to 74%, up from the low 60s, marking an all-time high [11][18] - Free cash flow was negative $11 million, an improvement of 30% compared to Q3 fiscal year 2025 [18] Business Line Data and Key Metrics Changes - Usage revenue increased by 29%, while subscription revenue grew by 26% year-over-year [16] - Gross booking volume reached $2.62 billion, growing 40% year-over-year [16] - Payment volume processed through Navan Cards was $1.13 billion, up 12% year-over-year [17] Market Data and Key Metrics Changes - Revenue from international customers represented 37% of total revenue in Q3 [17] - Customer satisfaction hit a high of 97%, with a Net Promoter Score (NPS) of 45, significantly above the industry average [7] Company Strategy and Development Direction - The company aims to drive sustained high growth across all customer segments, accelerate innovation, and maintain a balance between growth and profitability [12][13] - Focus on AI-driven experiences and leveraging data to enhance customer service and operational efficiency [9][12] - The company is positioned as an AI leader in travel and expense management, with a strong emphasis on integrating AI into its platform [10][11] Management's Comments on Operating Environment and Future Outlook - The current business travel environment remains robust, with expectations for continued strength through the fiscal year [15][16] - Management noted no significant impact from travel disruptions related to the government shutdown, with record performance in October [15] - The company anticipates Q4 to be seasonally lower than Q3, reflecting typical business travel patterns [24] Other Important Information - The CFO, Amy Bute, will leave the company on January 9, 2026, with Ann Giviskos serving as interim CFO [5] - The company has a strong balance sheet with $809 million in cash and $207 million in debt, supporting future growth initiatives [22] Q&A Session Summary Question: What is the outlook for enterprise business and share capture from incumbents? - Management sees strong momentum in enterprise, driven by customer satisfaction, market consolidation, and AI capabilities [27] Question: What drove the strength in gross booking volume and usage yield? - Growth in GBV is attributed to existing customer retention, ramping new customers, and new customer acquisition [29] Question: Are large enterprise deals complete implementations or partial? - Most enterprise deals involve multiple products at launch, indicating a stable and accelerating ramp-up [32] Question: How sustainable is the margin leverage seen this quarter? - Margin leverage is driven by efficiencies from AI support and is expected to be sustainable, though Q4 margins may compress seasonally [33] Question: What is the investment plan for PLG motion and expected revenue contribution? - Investments in Navan Edge and AI will continue, with expected revenue contributions more visible in fiscal year 2028 [36] Question: How does the company factor large deals into guidance? - Guidance incorporates active customers, ramping customers, and expected launches, using machine learning for forecasting [38] Question: Has the IPO impacted visibility and competitive positioning? - The IPO has increased market awareness and credibility, leading to more leads and reduced questions from potential clients [41] Question: What is the strategy for M&A opportunities? - The company is always looking for opportunities but currently believes in developing in-house capabilities, particularly in AI [52]

DXd ADC Portfolio & Approvals - Daiichi Sankyo's DXd ADC technology received 3 World ADC Awards in 2025[21, 23, 25] - ENHERTU has achieved 15 new regulatory approvals across 15 countries/regions and 94 extension approvals across 45 countries/regions as of CY2025[31] - DATROWAY received 1 accelerated approval for TROPION-Lung05 based on Breakthrough Therapy Designation (BTD)[31] - I-DXd in SCLC and R-DXd in PROC received BTDs, totaling 13 BTDs for the DXd ADC portfolio[31] Clinical Trial Results & Advancements - DESTINY-Breast11 (Neoadjuvant) demonstrated statistically significant and clinically meaningful improvement in pCR vs ddAC-THP in patients with high-risk HER2+ eBC[39, 41] - DESTINY-Breast05 (Post Neoadjuvant) showed a 53% reduction in the risk of invasive disease recurrence or death for T-DXd compared with T-DM1 in patients with HER2+ eBC[42, 44] - In TROPION-Breast02, DATROWAY demonstrated a statistically significant and clinically meaningful improvement of ~5 months in both mOS (23.7 vs 18.7 months) and mPFS vs chemotherapy (OS HR: 0.79)[46, 48] - DATROWAY achieved an ORR of 62% vs 293% for chemotherapy in TROPION-Breast02[50] Oncology Business Performance & Strategy - Daiichi Sankyo aims to deliver 900 Billion JPY in 5 years (FY2021 to 2025)[131] - ENHERTU delivered ¥5528 Billion in revenue in FY2024, with US and EU leading the way[134] - ENHERTU has treated 194000 patients globally[132, 134] - DATROWAY global net sales exceeded 10 Billion JPY in Q2 FY'25[157] Manufacturing and Supply - Daiichi Sankyo is expanding production capacity and enhancing capabilities to maximize supply volume for 5 DXd ADCs[190, 191] - The company is utilizing both in-house manufacturing and multiple CMOs to establish diversified manufacturing and supply routes[197]

Financial Data and Key Metrics Changes - The company reported that all nominees for election to the board have been duly elected, and the appointment of Simon & Edward as the independent registered public accounting firm for the fiscal year ending December 31, 2025, has been ratified [19] - An amendment to effect a reverse stock split of the company's common stock and an increase in the number of authorized shares from 100 million to 500 million have been approved [19] Business Line Data and Key Metrics Changes - No specific data on business lines or key metrics changes were provided in the meeting [20] Market Data and Key Metrics Changes - No specific market data or key metrics changes were discussed during the meeting [20] Company Strategy and Development Direction and Industry Competition - The company is focusing on increasing its authorized shares significantly, which may indicate plans for future growth or capital raising [19] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [20] Other Important Information - The meeting was conducted virtually, allowing shareholders worldwide to participate conveniently [2] - Stockholders were informed that the final vote totals would be included in a current report on Form 8-K filed with the Securities and Exchange Commission within four business days [6][19] Q&A Session All Questions and Answers - There were no questions from stockholders during the Q&A session [20]

Financial Data and Key Metrics Changes - The preliminary vote count indicates that all nominees for election to the board have been duly elected, and the appointment of Simon & Edward as the independent registered public accounting firm for the fiscal year ending December 31, 2025, has been ratified [19] - An amendment to effect a reverse stock split of the company's common stock and an increase in the number of authorized shares from 100 million to 500 million have each been approved [19] Business Line Data and Key Metrics Changes - No specific data on business line performance or key metrics was provided in the meeting [20] Market Data and Key Metrics Changes - No specific market data or key metrics were discussed during the meeting [20] Company Strategy and Development Direction - The company is focusing on governance changes, including the election of directors and amendments to its Articles of Incorporation, which may indicate a strategic shift towards enhancing shareholder value [19][20] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [20] Other Important Information - The meeting was conducted virtually, allowing shareholders worldwide to participate conveniently [2] - Stockholders were reminded that the meeting is not a public forum for purposes of SEC's Regulation FD, and no material non-public information would be disclosed [10][12] Q&A Session All Questions and Answers - There were no questions submitted by stockholders during the Q&A session, and the meeting concluded without addressing any inquiries [20]

OmniUltra Platform Overview - OmniUltra is the first and only transgenic chicken producing antibodies on a human framework with ultralong CDRH3s, similar to those found in cows[24] - Ultralong CDRH3s can reach binding pockets inaccessible to other antibodies, and can be cleaved to create Picobodies, the smallest functional antibody fragment[24] - OmniUltra is engineered for *in vivo* optimization, generating molecules pre-selected for function, affinity, and structural stability, potentially uncovering novel binding domains[27] - The platform leverages a transgenic chicken host to deliver biologically-optimized structured peptides, unlike phage display or other peptide discovery technologies[28] Competitive Advantages and Biological Intelligence - Antibodies generated *in vivo* are naturally optimized for specificity and developability[37] - The immune system in engineered transgenic animals creates optimized antibodies for human therapeutics, termed Biological Intelligence, increasing the efficiency and probability of success in therapeutic antibody discovery[37] - Greater evolutionary distance yields greater immunogenicity and more antibody diversity in chicken platforms[38] Epitope Coverage and Peptide Discovery - OmniUltra chickens are immunoresponsive to a variety of antigen targets[42] - Ultralong CDRH3 IgG clones bind to overlapping and novel epitopes[45] - OmniUltra can identify naturally-optimized peptide sequences that can be chemically synthesized as picobodies and retain antibody-like affinity and specificity to the immunized target[49] Market Opportunities and Expansion - The estimated total available commercial therapeutic market in 2034 is over $1 trillion, including peptides ($332 billion), bi-specifics ($460 billion), CAR-T ($224 billion), and radiopharma ($14 billion)[64] - Expansion into peptides provides an opportunity to drive service revenue and increases the potential audience of new partners by adding >130 peptide companies[66, 68]

Financial Data and Key Metrics Changes - The company reported a total of 36,085,978 shares of common stock outstanding as of the record date [4] - The company has 50,000 shares of Series C preferred stock outstanding entitled to vote at the meeting [4] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were provided in the meeting records Market Data and Key Metrics Changes - No specific market data or key metrics were provided in the meeting records Company Strategy and Development Direction and Industry Competition - The company proposed a reverse stock split of its common stock at a ratio of not less than one for 20 and not more than one for 50, with the exact timing and ratio to be determined by the Board of Directors [8][14] - The company also proposed to increase the number of authorized shares of common stock from 100 million to 500 million [9][15] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting Other Important Information - The meeting was conducted virtually, allowing shareholders worldwide to participate conveniently [2] - The company emphasized that any forward-looking statements made during the meeting are subject to significant risks and uncertainties [10][11] Q&A Session All Questions and Answers Question: Were there any questions from stockholders? - There were no questions submitted by stockholders during the Q&A session [18]

POWERING FORWARD DECEMBER 15, 2025 – INVESTOR PRESENTATION 1 Cautionary Statement This document has been prepared by WSP Global Inc. ("WSP" or the "Corporation") solely for information purposes. Prospectus Information A final base shelf prospectus of WSP dated August 8, 2024, containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in each of the provinces and territories of Canada. A copy of the final base shelf prospec ...

Investor Presentation Q3 Fiscal 2026 Safe Harbor Disclaimer This presentation contains "forward-looking statementsˮ within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Navan's anticipated total revenue, non-GAAP income (loss) from operations, and non-GAAP operating margin for the fiscal quarter and year ending January 31, 2026, the size of Navan's market opportunity, market trends, and the company's business strategy and plans. In s ...